McLaren Gould's profile picture

McLaren Gould

Executive Assistant To Chief Executive Officer at Aitia

McLaren Gould has a diverse work experience spanning from 2011 to 2023. They started their career at MIT Sloan School of Management, where they held roles in Global Programs and the Action Learning Program from 2011 to 2017. In 2018, McLaren worked as an Innovation Consultant, MBA Intern at Deimos Engenharia. From 2019 to 2021, they served as an HR Generalist and Executive Assistant to the Chief Executive Officer at IANS. McLaren then worked at Atlas Venture as an Executive Assistant from 2021 to 2022. Currently, McLaren holds the position of Manager, Operations & Office Administration at Stealth Mode Biotech, starting in June 2023.

McLaren Gould completed a Master of Business Administration - MBA degree in Business from The Lisbon MBA Católica | Nova in 2018. In the same year, they also obtained a Summer Immersion Program Certificate in Entrepreneurship/Entrepreneurial Studies from MIT Sloan School of Management. Prior to their MBA, McLaren attended Boston University - Frederick S. Pardee School of Global Studies (Pardee School), where they pursued a Bachelor of Arts (B.A.) degree in International Relations and Affairs. Additionally, McLaren has obtained certifications in Digital Marketing from General Assembly in March 2017, and in Product Management from General Assembly in March 2016.

Location

Boston, United States

Links

Previous companies

Atlas Venture logo
IANS logo

Org chart

Upgrade to view 0 reports


Teams

This person is not in any teams


Offices


A

Aitia

1 followers

Aitia is the leader in the application of Causal AI and Digital Twins to discover the next generation of breakthrough drugs. By leveraging the convergence of multi-omic patient data, high-performance computing, and causal learning and AI, Aitia is revealing the hidden biological mechanisms of disease to create Digital Twins of disease in oncology,neurodegenerative disorders, and immunology. Gemini Digital Twins are being used today to discover novel therapies and accelerate R&D in multiple myeloma, prostate cancer, Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease, with several more in development. Aitia’s partners include seven of the top ten pharmaceutical companies, leading academic research and medical centers, medical societies, leading multi-omic data companies, and patient advocacy groups globally.


Industries

Employees

51-200

Links